metricas

Vacunas

Sugerencias
Vacunas A review on non-small cell lung cancer
Información de la revista
Vol. 25. Núm. 2.
Páginas 149-288 (Abril - Junio 2024)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1171
Vol. 25. Núm. 2.
Páginas 149-288 (Abril - Junio 2024)

A review on non-small cell lung cancer

Revisión del cáncer de pulmón no microcítico
Visitas
1171
Sunil Kumar Vermaa, Minakshi Pandeyb, Renu Khareb, Devendra Singha,
Autor para correspondencia
devendrasingh.ibst@srmu.ac.in

Corresponding author.
a Faculty of Biotechnology, Institute of Biosciences & Technology, Shri Ramswaroop Memorial University, Lucknow Deva Road, Barabanki-225003, Uttar Pradesh, India
b Faculty of Biosciences, Institute of Biosciences & Technology, Shri Ramswaroop Memorial University, Lucknow Deva Road, Barabanki-225003, Uttar Pradesh, India
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Suplemento especial
Este artículo forma parte de:
Cancer vaccine development

Editado por: Alan G Raetz Butte College, Oroville, California, USA

Última actualización: Octubre 2024

Más datos
Abstract

Lung cancer is among the leading causes of death related to cancer globally, with NSCLC (non-small cell lung cancer) accounting for about 85% of all cases. NSCLC is characterized by a complex genetic landscape, with multiple driver mutations and epigenetic alterations that promote tumor progression and resistance to therapy. NSCLC is treated with immunotherapy, chemotherapy, radiation, surgery, or molecularly targeted therapy. However, a significant number of patients who had surgery are likely to experience local recurrence or distant metastases. Immunotherapy and targeted therapies have advanced rapidly in the last few years. Here, in this review, details related to NSCLC, its types, preventive measures, and risk factors, their symptoms, method of screening, diagnosis, and related treatment, and the latest updates related to NSCLC are discussed.

Keywords:
Cancer
Experimental drugs
Treatment
Diagnosis
Prevention
Resumen

El cáncer de pulmón se encuentra entre las principales causas de muerte relacionadas con el cáncer a nivel mundial, y el NSCLC (cáncer de pulmón de células no pequeñas) representa aproximadamente el 85 por ciento de todos los casos. El NSCLC se caracteriza por un panorama genético complejo, con múltiples mutaciones impulsoras y alteraciones epigenéticas que promueven la progresión del tumor y la resistencia a la terapia. El NSCLC se trata con inmunoterapia, quimioterapia, radiación, cirugía o terapia molecularmente dirigida. Sin embargo, es probable que un número significativo de pacientes sometidos a cirugía experimenten recurrencia local o metástasis a distancia. La inmunoterapia y las terapias dirigidas han avanzado rápidamente en los últimos años. Aquí, en esta revisión, se analizan los detalles relacionados con el NSCLC, sus tipos, medidas preventivas y factores de riesgo, sus síntomas, método de detección, diagnóstico y tratamiento relacionado, y las últimas actualizaciones relacionadas con el NSCLC.

Palabras clave:
Cáncer
fármacos experimentales
tratamiento
diagnóstico

Artículo

Opciones para acceder a los textos completos de la publicación Vacunas
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
References
[1]
M.S. Chandraprasad, A. Dey, M.K. Swamy.
1 - introduction to cancer and treatment approaches.
[2]
D. Singh, H. Pandey, V. Singh.
Natural products that target cancer stem cells.
Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics, pp. 169-186 http://dx.doi.org/10.4018/978-1-7998-9258-8.ch008
[3]
B. Vogelstein, K.W. Kinzler.
Cancer genes and the pathways they control.
Nat Med, 10 (2004), pp. 789-799
[4]
A. Upadhyay.
Cancer: an unknown territory; rethinking before going ahead.
Genes Dis, 8 (2020), pp. 655-661
[5]
N. Duma, R. Santana-Davila, J.R. Molina.
Non–small cell lung cancer: epidemiology, screening, diagnosis, and treatment.
Mayo Clin Proc, 94 (2019), pp. 1623-1640
[6]
R. Pirker.
Conquering lung cancer: current status and prospects for the future.
Pulmonology, 26 (2020), pp. 283-290
[7]
S.B. Clark, S. Alsubait.
Non–small cell lung cancer.
StatPearls,
[8]
H. Mithoowani, M. Febbraro.
Non-small-cell lung cancer in 2022: a review for general practitioners in oncology.
Curr Oncol., 29 (2022), pp. 1828-1839
[9]
C.S. Dela Cruz, L.T. Tanoue, R.A. Matthay.
Lung cancer: epidemiology, etiology, and prevention.
Clin Chest Med, 32 (2011), pp. 605-644
[10]
A.J. Alberg, J.G. Ford, J.M. Samet.
American College of Chest Physicians. Epidemiology of Lung Cancer: ACCP evidence-based clinical practice guidelines (2nd Edition).
Chest, 132 (2007), pp. 29S-55S
[11]
O.E. Tulunay, S.S. Hecht, S.G. Carmella, Y. Zhang, C. Lemmonds, S. Murphy, D.K. Hatsukami.
Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers.
Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol., 14 (2005), pp. 1283-1286
[12]
R.S. Herbst, J.V. Heymach, S.M. Lippman.
Lung cancer.
N Engl J Med, 359 (2008), pp. 1367-1380
[13]
C. Zappa, S.A. Mousa.
Non-small cell lung cancer: current treatment and future advances.
Transl Lung Cancer Res, 5 (2016), pp. 3
[14]
S. Darby, D. Hill, A. Auvinen, J.M. Barros-Dios, H. Baysson, F. Bochicchio, H. Deo, R. Falk, F. Forastiere, M. Hakama, I. Heid, L. Kreienbrock, M. Kreuzer, F. Lagarde, I. Mäkeläinen, C. Muirhead, W. Oberaigner, G. Pershagen, A. Ruano-Ravina, E. Ruosteenoja, A.S. Rosario, M. Tirmarche, L. Tomásek, E. Whitley, H.-E. Wichmann, R. Doll.
Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies.
[15]
D. Krewski, J.H. Lubin, J.M. Zielinski, M. Alavanja, V.S. Catalan, R.W. Field, J.B. Klotz, E.G. Létourneau, C.F. Lynch, J.I. Lyon, D.P. Sandler, J.B. Schoenberg, D.J. Steck, J.A. Stolwijk, C. Weinberg, H.B. Wilcox.
Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies.
Epidemiol Camb Mass, 16 (2005), pp. 137-145
[16]
D. Krewski, J.H. Lubin, J.M. Zielinski, M. Alavanja, V.S. Catalan, R.W. Field, J.B. Klotz, E.G. Létourneau, C.F. Lynch, J.L. Lyon, D.P. Sandler, J.B. Schoenberg, D.J. Steck, J.A. Stolwijk, C. Weinberg, H.B. Wilcox.
A combined analysis of North American case-control studies of residential radon and lung cancer.
J Toxicol Environ Health A, 69 (2006), pp. 533-597
[17]
W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato, E. Brambilla.
TNM classification of lung carcinoma.
Histological Typing of Lung and Pleural Tumours, pp. 67-70 http://dx.doi.org/10.1007/978-3-642-60049-4_4
[18]
W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato, E. Brambilla.
TNM classificationof malignant mesothelioma of the pleura.
Histological Typing of Lung and Pleural Tumours, pp. 71-72 http://dx.doi.org/10.1007/978-3-642-60049-4_5
[19]
P. Macchiarini, G. Fontanini, M.J. Hardin, H. Chuanchieh, D. Bigini, S. Vignati, R. Pingitore, C.A. Angeletti.
Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer.
J Thorac Cardiovasc Surg, 106 (1993), pp. 80-89
[20]
K.S. Albain, J.J. Crowley, M. LeBlanc, R.B. Livingston.
Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience.
J Clin Oncol Off J Am Soc Clin Oncol, 9 (1991), pp. 1618-1626
[21]
C.I. Amos, X. Wu, P. Broderick, I.P. Gorlov, J. Gu, T. Eisen, Q. Dong, Q. Zhang, X. Gu, J. Vijayakrishnan, K. Sullivan, A. Matakidou, Y. Wang, G. Mills, K. Doheny, Y.-Y. Tsai, W.V. Chen, S. Shete, M.R. Spitz, R.S. Houlston.
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1.
Nat Genet, 40 (2008), pp. 616-622
[22]
T.E. Thorgeirsson, F. Geller, P. Sulem, T. Rafnar, A. Wiste, K.P. Magnusson, A. Manolescu, G. Thorleifsson, H. Stefansson, A. Ingason, S.N. Stacey, J.T. Bergthorsson, S. Thorlacius, J. Gudmundsson, T. Jonsson, M. Jakobsdottir, J. Saemundsdottir, O. Olafsdottir, L.J. Gudmundsson, G. Bjornsdottir, K. Kristjansson, H. Skuladottir, H.J. Isaksson, T. Gudbjartsson, G.T. Jones, T. Mueller, A. Gottsäter, A. Flex, K.K.H. Aben, F. de Vegt, P.F.A. Mulders, D. Isla, M.J. Vidal, L. Asin, B. Saez, L. Murillo, T. Blondal, H. Kolbeinsson, J.G. Stefansson, I. Hansdottir, V. Runarsdottir, R. Pola, B. Lindblad, A.M. van Rij, B. Dieplinger, M. Haltmayer, J.I. Mayordomo, L.A. Kiemeney, S.E. Matthiasson, H. Oskarsson, T. Tyrfingsson, D.F. Gudbjartsson, J.R. Gulcher, S. Jonsson, U. Thorsteinsdottir, A. Kong, K. Stefansson.
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease.
Nature, 452 (2008), pp. 638-642
[23]
A.E.B. McLean, D.J. Barnes, L.K. Troy.
Diagnosing lung cancer: the complexities of obtaining a tissue diagnosis in the era of minimally invasive and personalised medicine.
J Clin Med, 7 (2018), pp. 163
[24]
M. Šutić, A. Vukić, J. Baranašić, A. Försti, F. Džubur, M. Samaržija, M. Jakopović, L. Brčić, J. Knežević.
Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management.
J Pers Med, 11 (2021), pp. 1102
[25]
R. Nooreldeen, H. Bach.
Current and future development in lung cancer diagnosis.
Int J Mol Sci, 22 (2021),
[26]
S.P. Power, F. Moloney, M. Twomey, K. James, O.J. O'Connor, M.M. Maher.
Computed tomography and patient risk: facts, perceptions and uncertainties.
World J Radiol, 8 (2016), pp. 902-915
[27]
C.-F. Cao, K.-L. Ma, H. Shan, T.-F. Liu, S.-Q. Zhao, Y. Wan, n. Jun-Zhang, H.-Q. Wang.
CT scans and cancer risks: a systematic review and dose-response meta-analysis.
BMC Cancer, 22 (2022), pp. 1238
[28]
L.K. Griffeth.
Use of PET/CT scanning in cancer patients: technical and practical considerations.
Proc Bayl Univ Med Cent, 18 (2005), pp. 321
[29]
R.A. Kauppinen, A.C. Peet.
Using magnetic resonance imaging and spectroscopy in cancer diagnostics and monitoring.
Cancer Biol Ther, 12 (2011), pp. 665-679
[30]
M. Haris, S.K. Yadav, A. Rizwan, A. Singh, E. Wang, H. Hariharan, R. Reddy, F.M. Marincola.
Molecular magnetic resonance imaging in cancer.
J Transl Med, 13 (2015), pp. 313
[31]
C. Adams, K.P. Banks.
Bone scan.
StatPearls,
[32]
R. Palmirotta, D. Lovero, P. Cafforio, C. Felici, F. Mannavola, E. Pellè, D. Quaresmini, M. Tucci, F. Silvestris.
Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology.
[33]
E. Ziv, J.C. Durack, S.B. Solomon.
The importance of biopsy in the era of molecular medicine.
Cancer J Sudbury Mass, 22 (2016), pp. 418-422
[34]
T.J. Paradis, J. Dixon, B.H. Tieu.
The role of bronchoscopy in the diagnosis of airway disease.
J Thorac Dis, 8 (2016), pp. 3826
[35]
M. Andolfi, R. Potenza, R. Capozzi, V. Liparulo, F. Puma, K. Yasufuku.
The role of bronchoscopy in the diagnosis of early lung cancer: a review.
J Thorac Dis, 8 (2016), pp. 3329-3337
[36]
E.P. Cantey, J.M. Walter, T. Corbridge, J.H. Barsuk.
Complications of thoracentesis: incidence, risk factors, and strategies for prevention.
Curr Opin Pulm Med, 22 (2016), pp. 378-385
[37]
K.S. Vyas, D.L. Davenport, V.A. Ferraris, S.P. Saha.
Mediastinoscopy: trends and practice patterns in the United States.
South Med J, 106 (2013), pp. 539-544
[38]
T. Chai, Y. Lin, M. Kang, J. Lin.
Thoracotomy versus video-assisted thoracoscopic resection of lung cancer.
Medicine (Baltimore), 98 (2019),
[39]
B.D. Wiederhold, O. Amr, P. Modi, M.C. O'Rourke.
Thoracentesis.
StatPearls,
[40]
N.L. Henry, D.F. Hayes.
Cancer biomarkers.
Mol Oncol, 6 (2012), pp. 140-146
[41]
P. Gamble, R. Jaroensri, H. Wang, F. Tan, M. Moran, T. Brown, I. Flament-Auvigne, E.A. Rakha, M. Toss, D.J. Dabbs, P. Regitnig, N. Olson, J.H. Wren, C. Robinson, G.S. Corrado, L.H. Peng, Y. Liu, C.H. Mermel, D.F. Steiner, P.-H.C. Chen.
Determining breast cancer biomarker status and associated morphological features using deep learning.
[42]
M. Chen, J. Huang, Z. Zhu, J. Zhang, K. Li.
Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.
BMC Cancer, 13 (2013), pp. 1-15
[43]
P. Kumar, S.K. Verma, S. Rai, P.S. Prakash, D. Chitara.
Role of homocysteine metabolism in cardiovascular diseases.
Homocysteine Metabolism in Health and Disease, pp. 257-276 http://dx.doi.org/10.1007/978-981-16-6867-8_14
[44]
V.K. Sarhadi, G. Armengol.
Molecular biomarkers in cancer.
Biomolecules, 12 (2022), pp. 1021
[45]
H. Lemjabbar-Alaoui, O. Hassan, Y.-W. Yang, P. Buchanan.
Lung cancer: biology and treatment options.
Biochim Biophys Acta, 1856 (2015), pp. 189-210
[46]
G.S. Jones, D.R. Baldwin.
Recent advances in the management of lung cancer.
Clin Med, 18 (2018), pp. s41-s46
[47]
S. Yang, Z. Zhang, Q. Wang.
Emerging therapies for small cell lung cancer.
J Hematol Oncol, 12 (2019), pp. 1-11
[48]
H. Cai, Y. Wang, D. Qin, Y. Cui, H. Zhang.
Advanced surgical technologies for lung cancer treatment: current status and perspectives.
[49]
N. Deboever, K.G. Mitchell, H.A. Feldman, T. Cascone, B. Sepesi.
Current surgical indications for non-small-cell lung cancer.
[50]
G. Wright, R.L. Manser, G. Byrnes, D. Hart, D.A. Campbell.
Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials.
Thorax, 61 (2006), pp. 597-603
[51]
F. McDonald, M.D. Waele, L.E.L. Hendriks, C. Faivre-Finn, A.-M.C. Dingemans, P.E.V. Schil.
Management of stage I and II nonsmall cell lung cancer.
[52]
A. Levy, C. Faivre-Finn.
Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more.
Ann Transl Med, 8 (2020), pp. 1114
[53]
B. Liu, Z. Wang, H. Zhao, S. Gao, H. Wang, Y. Zhang, K. Fan, R. Tao, Y. Li, J. Feng, Y. Sun, J. Zhang, G. Zhang.
The Value of radiotherapy in patients with resectable stage IIIA non–small-cell lung cancer in the era of individualized treatment: a population-based analysis.
Clin Lung Cancer, 24 (2023), pp. 18-28
[54]
P. Kumar, S. Rai, S.K. Verma, P.S. Prakash, D. Chitara.
Classification, mode of action and uses of various immunomodulators.
Immunomodulators and Human Health, pp. 3-38 http://dx.doi.org/10.1007/978-981-16-6379-6_1
[55]
L. Yu, J. Xu, R. Qiao, B. Han, H. Zhong, R. Zhong.
Pathological stage N1 limited-stage small-cell lung cancer patients can benefit from surgical resection.
Clin Lung Cancer, 24 (2023), pp. e1-e8
[56]
Q. Guo, L. Liu, Z. Chen, Y. Fan, Y. Zhou, Z. Yuan, W. Zhang.
Current treatments for non-small cell lung cancer.
[57]
S.H. Lee.
Chemotherapy for lung cancer in the era of personalized medicine.
Tuberc Respir Dis, 82 (2019), pp. 179-189
[58]
M. Shao, J. Yao, Y. Wang, L. Zhao, B. Li, L. Li, Z. Wu, Z. Chen, J. Fan, F. Qiu.
Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial.
Signal Transduct Target Ther, 8 (2023), pp. 1-3
[59]
B.J. Solomon, T. Mok, D.-W. Kim, Y.-L. Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, S. Iyer, A. Reisman, K.D. Wilner, J. Tursi, F. Blackhall.
PROFILE 1014 investigators. first-line crizotinib versus chemotherapy in ALK-positive lung cancer.
N Engl J Med, 371 (2014), pp. 2167-2177
[60]
M. Ming, Z. Ma, Y. Xu, F. Sun, X. Cui.
Carboplatin-based nanomedicine to enhance the anticancer effect in SK-NEP-1 wilms' tumor cells.
Iran J Pharm Res IJPR, 16 (2017), pp. 1305-1311
[61]
S. Dasari, P.B. Tchounwou.
Cisplatin in cancer therapy: molecular mechanisms of action.
Eur J Pharmacol, 740 (2014), pp. 364-378
[62]
N.G. Farha, A. Kasi.
Docetaxel.
StatPearls,
[63]
M.Y. Ho, J.R. Mackey.
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
Cancer Manag Res, 6 (2014), pp. 253-259
[64]
K.R. Hande.
Etoposide: four decades of development of a topoisomerase II inhibitor.
Eur J Cancer Oxf Engl 1990, 34 (1998), pp. 1514-1521
[65]
B.F. Issell, S.T. Crooke.
Etoposide (VP-16-213).
Cancer Treat Rev, 6 (1979), pp. 107-124
[66]
G. Reyhanoglu, P. Tadi.
Etoposide.
StatPearls,
[67]
S. Noble, K.L. Goa.
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
[68]
K. Samanta, S. Setua, S. Kumari, M. Jaggi, M.M. Yallapu, S.C. Chauhan.
Gemcitabine combination nano therapies for pancreatic cancer.
Pharmaceutics, 11 (2019), pp. 574
[69]
M.S. Hassan, N. Awasthi, S. Ponna, U. von Holzen.
Nab-paclitaxel in the treatment of gastrointestinal cancers—improvements in clinical efficacy and safety.
Biomedicines, 11 (2023), pp. 2000
[70]
J.S. Kim, K.J. Suh, D.-W. Lee, G. Woo, M. Kim, S.H. Kim, H.S. Ryu, K.-H. Lee, T.-Y. Kim, S.-W. Han, S.Y. Park, I.A. Park, J.H. Kim, S.-A. Im.
A real-world efficacy of nab-paclitaxel monotherapy in metastatic breast cancer.
Cancer Res Treat Off J Korean Cancer Assoc, 54 (2022), pp. 488-496
[71]
Z. Tian, W. Yao.
Albumin-bound paclitaxel: worthy of further study in sarcomas.
[72]
T.M. Abu Samaan, M. Samec, A. Liskova, P. Kubatka, D. Büsselberg.
Paclitaxel's mechanistic and clinical effects on breast cancer.
Biomolecules, 9 (2019), pp. 789
[73]
B.A. Weaver.
How taxol/paclitaxel kills cancer cells.
Mol Biol Cell, 25 (2014), pp. 2677-2681
[74]
L. Zhu, L. Chen.
Progress in research on paclitaxel and tumor immunotherapy.
Cell Mol Biol Lett, 24 (2019), pp. 40
[75]
K. Al-Saleh, C. Quinton, P.M. Ellis.
Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis.
[76]
V. Beljanski.
Pemetrexed.
xPharm: The Comprehensive Pharmacology Reference, pp. 1-5 http://dx.doi.org/10.1016/B978-008055232-3.63731-6
[77]
E. González-Burgos, M.P. Gómez-Serranillos.
Chapter 4 - vinca alkaloids as chemotherapeutic agents against breast cancer.
Discovery and Development of Anti-Breast Cancer Agents from Natural Products, pp. 69-101 http://dx.doi.org/10.1016/B978-0-12-821277-6.00004-0
[78]
D. Townsend.
Vinorelbine.
xPharm: The Comprehensive Pharmacology Reference, pp. 1-4 http://dx.doi.org/10.1016/B978-008055232-3.62855-7
[79]
R. Arriagada, A. Dunant, J.-P. Pignon, B. Bergman, M. Chabowski, D. Grunenwald, M. Kozlowski, C. Le Péchoux, R. Pirker, M.-I.S. Pinel, M. Tarayre, T. Le Chevalier.
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer.
J Clin Oncol, 28 (2010), pp. 35-42
[80]
A.T. Shaw, D.-W. Kim, K. Nakagawa, T. Seto, L. Crinó, M.-J. Ahn, T. De Pas, B. Besse, B.J. Solomon, F. Blackhall, Y.-L. Wu, M. Thomas, K.J. O'Byrne, D. Moro-Sibilot, D.R. Camidge, T. Mok, V. Hirsh, G.J. Riely, S. Iyer, V. Tassell, A. Polli, K.D. Wilner, P.A. Jänne.
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
N Engl J Med, 368 (2013), pp. 2385-2394
[81]
Z. Ye, Y. Huang, J. Ke, X. Zhu, S. Leng, H. Luo.
Breakthrough in targeted therapy for non-small cell lung cancer.
Biomed Pharmacother, 133 (2021),
[82]
C. Yuan, D. Chen, S. Wang.
Drug confirmation by mass spectrometry: identification criteria and complicating factors.
Clin Chim Acta, 438 (2015), pp. 119-125
[83]
M. Yuan, L.-L. Huang, J.-H. Chen, J. Wu, Q. Xu.
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Signal Transduct Target Ther, 4 (2019), pp. 1-14
[84]
B.A. Chan, B.G.M. Hughes.
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
Transl Lung Cancer Res, 4 (2015), pp. 36-54
[85]
P.M. Forde, D.S. Ettinger.
Targeted therapy for non-small-cell lung cancer: past, present and future.
Expert Rev Anticancer Ther, 13 (2013), pp. 745-758
[86]
T. Zubair, D. Bandyopadhyay.
Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities.
Int J Mol Sci, 24 (2023), pp. 2651
[87]
D. Brazel, G. Kroening, M. Nagasaka.
Non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: diagnosis and treatment options.
Biodrugs, 36 (2022), pp. 717-729
[88]
G. Bethune, D. Bethune, N. Ridgway, Z. Xu.
Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.
J Thorac Dis, 2 (2010), pp. 48-51
[89]
M. Riudavets, I. Sullivan, P. Abdayem, D. Planchard.
Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
[90]
I.A. Vathiotis, D. Bafaloukos, K.N. Syrigos, G. Samonis.
Evolving treatment landscape of HER2-mutant non-small cell lung cancer: trastuzumab deruxtecan and beyond.
[91]
B. Ricciuti, M. Brambilla, G. Metro, S. Baglivo, R. Matocci, M. Pirro, R. Chiari.
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.
Med Oncol Northwood Lond Engl, 34 (2017), pp. 105
[92]
H.J. Hwang, M.Y. Kim, C.-M. Choi, J.C. Lee.
Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer.
Medicine (Baltimore), 98 (2019),
[93]
A.T. Shaw, J.A. Engelman.
ALK in lung cancer: past, present, and future.
J Clin Oncol, 31 (2013), pp. 1105
[94]
D.S. Hong, M.G. Fakih, J.H. Strickler, J. Desai, G.A. Durm, G.I. Shapiro, G.S. Falchook, T.J. Price, A. Sacher, C.S. Denlinger, Y.-J. Bang, G.K. Dy, J.C. Krauss, Y. Kuboki, J.C. Kuo, A.L. Coveler, K. Park, T.W. Kim, F. Barlesi, P.N. Munster, S.S. Ramalingam, T.F. Burns, F. Meric-Bernstam, H. Henary, J. Ngang, G. Ngarmchamnanrith, J. Kim, B.E. Houk, J. Canon, J.R. Lipford, G. Friberg, P. Lito, R. Govindan, B.T. Li.
KRASG12C inhibition with sotorasib in advanced solid tumors.
N Engl J Med, 383 (2020), pp. 1207-1217
[95]
P. Manolakos, L.D. Ward.
A critical review of the prognostic and predictive implications of KRAS and STK11 mutations and co-mutations in metastatic non-small lung cancer.
J Pers Med, 13 (2023), pp. 1010
[96]
S. Park, B.-C. Ahn, S.W. Lim, J.-M. Sun, H.R. Kim, M.H. Hong, S.-H. Lee, J.S. Ahn, K. Park, Y.L. Choi, B.C. Cho, M.-J. Ahn.
Characteristics and outcome of ROS1-positive non–small cell lung cancer patients in routine clinical practice.
J Thorac Oncol, 13 (2018), pp. 1373-1382
[97]
A.T. Shaw, S.-H.I. Ou, Y.-J. Bang, D.R. Camidge, B.J. Solomon, R. Salgia, G.J. Riely, M. Varella-Garcia, G.I. Shapiro, D.B. Costa, R.C. Doebele, L.P. Le, Z. Zheng, W. Tan, P. Stephenson, S.M. Shreeve, L.M. Tye, J.G. Christensen, K.D. Wilner, J.W. Clark, A.J. Iafrate.
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
N Engl J Med, 371 (2014), pp. 1963-1971
[98]
S. Takamori, T. Matsubara, N. Haratake, G. Toyokawa, T. Fujishita, R. Toyozawa, K. Ito, M. Yamaguchi, K. Taguchi, T. Okamoto, T. Seto.
Targeted therapy for RET fusion lung cancer: breakthrough and unresolved issue.
[99]
T. Fujino, K. Suda, T. Mitsudomi.
Lung cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and future challenges.
Lung Cancer Targets Ther, 12 (2021), pp. 35-50
[100]
C.G. O'Leary, V. Andelkovic, R. Ladwa, N. Pavlakis, C. Zhou, F. Hirsch, D. Richard, K. O'Byrne.
Targeting BRAF mutations in non-small cell lung cancer.
Transl Lung Cancer Res, 8 (2019), pp. 1119-1124
[101]
S. Daum, H. Hagen, E. Naismith, D. Wolf, A. Pircher.
The role of anti-angiogenesis in the treatment landscape of non-small cell lung cancer – new combinational approaches and strategies of neovessel inhibition.
Front Cell Dev Biol, (2021), pp. 8
[102]
A. Alshangiti, G. Chandhoke, P.M. Ellis.
Antiangiogenic therapies in non-small-cell lung cancer.
Curr Oncol Tor Ont, 25 (2018), pp. S45-S58
[103]
L. Yang, L. Wang, Y. Zhang.
Immunotherapy for lung cancer: advances and prospects.
Am J Clin Exp Immunol, 5 (2016), pp. 1-20
[104]
E. Massarelli, V. Papadimitrakopoulou, J. Welsh, C. Tang, A.S. Tsao.
Immunotherapy in lung cancer.
Transl. Lung Cancer Res., 3 (2014), pp. 53
[105]
D. Rocco, L. Della Gravara, A. Ragone, L. Sapio, S. Naviglio, C. Gridelli.
Prognostic factors in advanced non-small cell lung cancer patients treated with immunotherapy.
[106]
N. Krzyżanowska, P. Krawczyk, K. Wojas-Krawczyk, T. Kucharczyk, J. Milanowski.
Immunotherapy in non-small-cell lung cancer patients with driver alterations: a new strategy?.
[107]
S. Stock-Martineau, K. Magner, K. Jao, P. Wheatley-Price.
Challenges of immunotherapy in stage IV non–small-cell lung cancer.
JCO Oncol Pract, 17 (2021), pp. 465-471
[108]
Y. Xu, Y. Liu, Y. Ge, H. Li, Y. Zhang, L. Wang.
Drug resistance mechanism and reversal strategy in lung cancer immunotherapy.
Front Pharmacol, 14 (2023),
[109]
D. Fedor, W.R. Johnson, S. Singhal.
Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes.
Surg Oncol, 22 (2013), pp. 156-161
[110]
H. Uramoto, F. Tanaka.
Recurrence after surgery in patients with NSCLC.
Transl. Lung Cancer Res., 3 (2014), pp. 242-249
[111]
B.J. Schneider, N. Ismaila, J. Aerts, C. Chiles, M.E. Daly, F.C. Detterbeck, J.W.D. Hearn, S.I. Katz, N.B. Leighl, B. Levy, B. Meyers, S. Murgu, L. Nekhlyudov, E.S. Santos, N. Singh, J. Tashbar, D. Yankelevitz, N. Altorki.
Lung Cancer surveillance after definitive curative-intent therapy: ASCO guideline.
J Clin Oncol, 38 (2020), pp. 753-766
[112]
Y. Chen, W. Guan, C. Zhong, J. Deng, M. Hu, W. Mo, X. Xie, S. Li, C. Zhou, X. Lin.
Case report: spontaneous remission in lung carcinoma with a late relapse after adjuvant immunotherapy: exceptional tumor micro-environment.
Front Immunol, 14 (2023), pp. 1106090
[113]
J. Le-Rademacher, S. Dahlberg, J.J. Lee, A.A. Adjei, S.J. Mandrekar.
Biomarker clinical trials in lung cancer: design, logistics, challenges, and practical considerations.
J Thorac Oncol, 13 (2018), pp. 1625-1637
[114]
J. Subramanian, T. Regenbogen, G. Nagaraj, A. Lane, S. Devarakonda, G. Zhou, R. Govindan.
Review of ongoing clinical trials in non–small-cell lung cancer: a status report for 2012 from the ClinicalTrials.Gov web site.
[115]
E.B. Garon, P.A. Abarca, J.L. Strunck, D. Nameth, C. Neumann, B. Wolf, K.Y. Kim, C. Marx, R.M. Elashoff.
Clinical trials in non-small cell lung cancer with biomarker-driven treatment allocation: ready or not, here we come.
Crit Rev Oncog, 20 (2015), pp. 339-347
[116]
B. Zaric, B. Perin, A. Ilic, I. Kopitovic, J. Matijasevic, L. Andrijevic, N. Secen, J. Stanic, M. Bijelovic, Z. Kosjerina, M. Antonic.
Clinical trials in advanced stage lung cancer: a survey of patients' opinion about their treatment.
Multidiscip Respir Med, 6 (2011), pp. 20
[117]
D. Singh, V. Agarwal.
Herbal antibacterial remedy against upper respiratory infection causing bacteria and in vivo safety analysis.
Vegetos, 35 (2022), pp. 264-268
[118]
S. Devendra, A. Vishnu.
A review on the COVID-19, its history, diagnostic approaches, role of herbs and current world scenario.
Biomedicine, 41 (2021), pp. 328-332
[119]
D. Singh, V. Agarwal.
Screening of antimicrobial, anti-quorum sensing activity and cytotoxicity of origanum oil against Gram-positive and Gram-negative bacteria.
Biomedicine, 41 (2021), pp. 599-603
[120]
D. Singh, D. Sharma, V. Agarwal.
Screening of anti-microbial, anti-biofilm activity, and cytotoxicity analysis of a designed polyherbal formulation against shigellosis.
J Ayurveda Integr Med, 12 (2021), pp. 601-606
[121]
D. Singh, V. Agarwal.
An in vivo acute toxicity and anti-shigellosis effect of designed formulation on rat.
J Ayurveda Integr Med, 14 (2023),
[122]
D. Singh, V. Singh, S. Bhushan Mishra, D. Sharma, V. Agarwal.
Evaluation of anti-biofilm, anti-quorum, anti-dysenteric potential of designed polyherbal formulation: in vitro and in vivo study.
J Appl Biomed, 20 (2022), pp. 7-14
[123]
N.K. Shrivastava, D. Singh, S.K. Verma, A.P. Singh, A. Srivastava.
Toxicology assessment of polymeric material for implants.
Assessment of Polymeric Materials for Biomedical Applications, pp. 33-54
[124]
V. Chauhan, A. Pandey, A. Rakshit, G. Mahajan, S.S. Kanwar, V.K. Dhiman, D. Singh.
Musculoskeletal and neuromuscular dysfunction due to covid-19 infection: a review.
[125]
V. Chauhan, A. Rakshit, V.K. Dhiman, G. Mahajan, A. Pnadey, S.S. Kanwar, D. Singh.
Effectiveness of the vaccine (Covaxin®) on different age groups of people: a pilot study.
[126]
S. Dohare, D. Singh, D. Sharma, V. Agarwal.
Effect of Staphylococcus epidermidis on Pseudomonas aeruginosa biofilm in mixed-species culture.
J Exp Biol Agric Sci, 9 (2021), pp. 325-334
[127]
N. Singh, S. Agrawal, S. Jiwnani, D. Khosla, P.S. Malik, A. Mohan, P. Penumadu, K.T. Prasad.
Lung cancer in India.
J Thorac Oncol, 16 (2021), pp. 1250-1266
[128]
A. Aggarwal, G. Lewison, S. Idir, M. Peters, C. Aldige, W. Boerckel, P. Boyle, E.L. Trimble, P. Roe, T. Sethi, J. Fox, R. Sullivan.
The state of lung cancer research: a global analysis.
J Thorac Oncol, 11 (2016), pp. 1040-1050
[129]
K. Inamura.
Lung cancer: understanding its molecular pathology and the 2015 WHO classification.
Front Oncol, (2017), pp. 7
[130]
A.B. Sandler, A.C. Buzaid.
Lung cancer: a review of current therapeutic modalities.
Lung, 170 (1992), pp. 249-265
[131]
S. Eckhouse, G. Lewison, R. Sullivan.
Trends in the global funding and activity of cancer research.
[132]
R. Chen, R. Manochakian, L. James, A.-G. Azzouqa, H. Shi, Y. Zhang, Y. Zhao, K. Zhou, Y. Lou.
Emerging therapeutic agents for advanced non-small cell lung cancer.
J Hematol Oncol, 13 (2020), pp. 58
[133]
S. Srivastava, D. Singh, S.K. Verma, M. Pandey, A. Sharma, H. Pandey, A. Mishra.
Recent advancements in cancer vaccines: a systematic review.
[134]
A. Kushwaha, V. Agarwal.
Autophagy at the crossroad of obesity-mediated cancer progression.
[135]
A. Kushwaha, R.S. Verma, V. Agarwal.
Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl) homoserine lactone induces calcium signaling-dependent crosstalk between autophagy and apoptosis in human macrophages.
Cell Signal, 99 (2022 Nov), pp. 110441
[136]
A. Kushwaha, V. Kumar, V. Agarwal.
Pseudomonas quinolone signal induces organelle stress and dysregulates inflammation in human macrophages.
Biochim Biophys Acta Gen Subj, 1867 (2023 Feb), pp. 130269
[137]
A. Kushwaha, V. Agarwal.
Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-L-homoserine lactone mediates Ca+2 dysregulation, mitochondrial dysfunction, and apoptosis in human peripheral blood lymphocytes.
asdasdasd
Opciones de artículo
Herramientas